Gestational thyroid function abnormalities in conditions of mild iodine deficiency: early screening versus continuous monitoring of maternal thyroid status

Mariacarla Moleti1, Vincenzo Pio Lo Presti1, Filiberto Mattina1, Alfredo Mancuso2, Antonio De Vivo2, Grazia Giorgianni3, Beatrice Di Bella1, Francesco Trimarchi1 and Francesco Vermiglio1

1Dipartimento Clinico-Sperimentale di Medicina e Farmacologia- Sezione di Endocrinologia, 2Dipartimento di Scienze della Riproduzione, Sezione di Patologia Ostetrica and 3Dipartimento di Scienze Biochimiche, Fisiologiche e della Nutrizione- Servizio di Biochimica Clinica, University of Messina, 98125 Messina, Italy

(Correspondence should be addressed to F Vermiglio who is now at Cattedra di Endocrinologia, Policlinico Universitario, Via Consolare Valeria, 98125 Messina, Italy; Email: francesco.vermiglio@unime.it)

Abstract

Objective: To longitudinally evaluate the timing of maternal thyroid underfunction occurrence in mildly iodine-deficient (ID) pregnant women, and ultimately assess the benefit of thyroid function testing at early gestation only in identifying maternal thyroid underfunction.

Participants/methods: Serum free-thyroxine and TSH were measured in 220 consecutive women once in early pregnancy (by week 12) and twice per trimester subsequently. Anti-thyroperoxidase and anti-thyroglobulin were also determined at initial and final observation.

Results: Thyroid autoantibodies were detectable in 8.2% women. Overall, the prevalence of hypothyroidism over the course of gestation was 11.8% (26/220), with a relative risk of hypothyroidism in antibody-positive women of 5.0 ($\chi^2$ 20.02, P $<$ 0.0005). Nonetheless, almost 70% hypothyroid women tested negative for thyroid autoantibodies. Fifteen/26 (57.7%) hypothyroid women were identified at presentation, and the remaining 11 at either early (6/11) or late (5/11) phases of the 2nd trimester. Isolated hypothyroxinemia was observed in 56/220 (25.4%) women, mostly from the 2nd trimester onwards.

Conclusions: In mildly ID areas thyroid function testing early in gestation seems to be only partly effective in identifying thyroid underfunction in pregnant women. Indeed, in our series more than 40% hypothyroid women would not have been diagnosed had we limited our observation to early thyroid function tests alone. Although thyroid autoimmunity carried a 5-fold increased risk of hypothyroidism, iodine deficiency seems to be a major determinant in the occurrence of thyroid underfunction. Adequate iodine supplementation should be strongly recommended to meet the increased hormone demand over gestation.

European Journal of Endocrinology 160 611–617

Introduction

There is a known association between untreated maternal hypothyroidism and increased risk of several adverse outcomes for both mother and foetus at all stages of pregnancy (1, 2). Moreover, children born to mothers who experience even mild thyroid insufficiency at early gestational stages may be at risk for neuro-motor and cognitive deficits (3–5). In view of the severity of these consequences, and the awareness that they may be successfully prevented by prompt therapeutic intervention, many have recommended that thyroid function screening be routinely performed in pregnant women (6–8). Conversely, other investigators recommend thyroid function evaluation only in symptomatic women or in those with a personal history of thyroid disease (9–12). In the latest guidelines for the management of maternal thyroid dysfunction during pregnancy the authors conclude that recommending universal screening may be premature. Nonetheless, the expert panel does agree that maternal thyroid function testing is advisable in selected groups of women considered to be at high risk for thyroid disease (aggressive targeted case-finding) (13).

Whatever the strategy, i.e. universal screening or case-finding, there is broad agreement on the advisability of performing maternal thyroid function tests as early as possible after conception. Performing the tests at this early stage, however, could pose the risk that any maternal thyroid underfunction occurring later in gestation might not be picked up. In an attempt to assess this risk, we conducted an observational study on a cohort of consecutive pregnant women living in a mildly iodine-deficient (ID) area, whose thyroid function...
had been longitudinally monitored throughout gestation. The main aim of this study was therefore, to evaluate the timing of maternal thyroid failure occurrence in mildly iodine-deficiency and ultimately assess whether or not maternal thyroid function testing performed at an early stage in gestation only is in fact appropriate in detecting maternal thyroid underfunction in pregnant women from mildly ID areas.

**Subjects and methods**

**Area studied, clinical monitoring programme and participants**

The study was carried out in a presently mildly ID (median urinary iodine excretion (UIE) 99.7 μg/24 h; goitre in school children 16.3%) area of North-eastern Sicily that was previously classified as moderately-severely or moderately ID (1976–1980 UIE 25.5±23.6 μg/24 h; goitre in school children 65%; 1989–1991 UIE 48.1±38.2 μg/24 h; goitre in school children 31.7%) (14, 15). A wide range of neuro-intellectual disorders have been reported in school children from the area and attributed to various degrees of maternal thyroid insufficiency occurring during gestation (3, 15–17). Based on this evidence, we set up a monitoring programme to track maternal thyroid function over the full course of gestation and, later on, a programme of iodine prophylaxis aimed at preventing/correcting any maternal thyroid insufficiency occurring during gestation in order to ultimately avoid neuro-behavioural and intellectual disorders in progeny was offered on a voluntary basis (18).

All pregnant women living in this area were invited to participate in our prevention programme. Women were first sampled not later than week 12 at first trimester and twice more in the second and third trimester (at ~6 week intervals). Thyroid function testing included serum free-thyroxine (FT4) and TSH determinations. In assessing maternal thyroid function, we refer to both serum FT4 and TSH internal trimester-specific reference intervals calculated in a cohort of consecutive long-term iodine-supplemented healthy anti-thyroperoxidase (TPO-Ab) antibody-negative pregnant women (18). At initial and final sampling TPO-Ab and anti-thyroglobulin (Tg-Ab) antibodies were also determined.

All women found to be subclinically or overtly hypothyroid throughout gestation were given substitutive levo-T4 (l-T4). Women with mildly isolated hypothyroxinemia (IH, serum FT4 values below the lower limit of the trimester-specific reference range and TSH concentrations within the trimester-specific reference range), were also given substitutive l-T4, in line with the purely experimental design of the study.

To date, 426 pregnant women have been referred to our outpatient clinic. For the purposes of this study, 108/426 women were ineligible because they were receiving l-T4 replacement or semi-suppressive therapy for post-surgical hypothyroidism or nodular goitre prior to becoming pregnant. A further 98/426 women did not fulfill inclusion criteria either because they were not enrolled at early pregnancy or did not complete the scheduled follow up. The remaining 220 women, who had never been tested for thyroid dysfunction prior to becoming pregnant, made up our sample study. These women were variously iodine-supplemented. Indeed, in addition to the regular use of iodised salt, more than one half of them also received multivitamin compounds specifically prepared for pregnancy and containing iodine (100–150 μg).

The study was approved by the Ethical Committee of the 'G Martino' Polyclinic, Messina. Informed consent was obtained from all the women recruited.

**Measurements**

Maternal circulating TSH and FT4, TPO-Ab and Tg-Ab (electrochemiluminescence immunoassay (ECLIA)) were determined using commercial kits supplied by Roche Diagnostics, GmbH. Precision profiles showed inter and intra-assay coefficients of variation <5% over the entire measurement range.

**Statistical analysis**

Unless otherwise specified data are expressed as mean ± s.d. Statistical analysis was performed using the χ² or Fisher exact tests when appropriate, for categorical data.

**Results**

The clinical and biochemical features at presentation of the 220 studied women are reported in Table 1. TPOAb and/or TgAb were detectable in 18/220 (8.2%) women.

**Thyroid function abnormalities over gestation**

**Raised TSH with or without decreased FT4 (overt hypothyroidism (OH) or subclinical hypothyroidism (SCH))** At initial observation, 205/220 (93.2%) women showed normal TSH values. The remaining 15/220 (6.8%) women had raised TSH (>2.3 mIU/l), and four of them also had serum FT4 below the lowest trimester-specific reference range (11.9 pmol/l: Fig. 1, panel a). One third of these women (5/15) were anti-thyroid antibody-positive.

During the second trimester, a further 11 women showed TSH concentrations that were higher than the normal trimester-specific upper limit (2.8 mIU/l), with abnormally low FT4 concentrations (<10.4 pmol/l) for gestational age in three of them (Fig. 1, panels b and c). Anti-thyroid antibodies were positive in 3/11 (27.3%) hypothyroid women.
Table 1 Characteristics of the studied pregnant women at recruitment (n=220).

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>n (% of total)</th>
<th>Mean ± s.o.</th>
<th>Median</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal age (years)</td>
<td>220 (100)</td>
<td>–</td>
<td>29</td>
<td>17–40</td>
</tr>
<tr>
<td>Gestational age (weeks)</td>
<td>10.1 ± 1.8</td>
<td>10</td>
<td>5–12</td>
<td></td>
</tr>
<tr>
<td>≤ 8 weeks</td>
<td>57 (25.9)</td>
<td>7.1 ± 1.0</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>9–12 weeks</td>
<td>163 (74.1)</td>
<td>11.0 ± 1.1</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Parity</td>
<td>0</td>
<td>81 (36.8)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>1</td>
<td>74 (33.6)</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>≥ 2</td>
<td>65 (29.5)</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>FT₄ (pmol/l)</td>
<td>220 (100)</td>
<td>15.7 ± 2.6</td>
<td>15.7</td>
<td>10.3–26.2</td>
</tr>
<tr>
<td>TSH (mIU/l)</td>
<td>220 (100)</td>
<td>1.06 ± 0.97</td>
<td>0.85</td>
<td>0.01–6.5</td>
</tr>
<tr>
<td>TPO and/or Tg Abs positivity</td>
<td>18 (8.2)</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Urinary iodine excretion (µg/l)</td>
<td>220 (100)</td>
<td>96</td>
<td>50–385</td>
<td></td>
</tr>
</tbody>
</table>

Finally, over the third trimester, in none of the women was TSH found to exceed the upper trimester-specific limit (3.0 mIU/l; Fig. 1, panels d and e). Overall, overt or SCH affected 26/220 (11.8%) women, eight of whom (30.7%) were anti-thyroid antibody-positive.

Isolated low serum FT₄ concentrations and normal serum TSH (IH) At initial observation, 7/220 (3.2%) women had IH, with FT₄ concentrations below the lower limit for gestational age but normal TSH levels (Fig. 1, panel a). Of these, only one was anti-thyroid antibody-positive.

A gradual reduction in FT₄ concentrations was observed in a high proportion of women over the course of the second trimester; these were found to fall below the lower limit in 28 women, despite TSH concentrations remaining consistently within the normal range (Fig. 1, panels b and c). Anti-thyroid antibodies were positive in 3/28 of these women.

Finally, during the third trimester of gestation, 21 more women, none of whom were TPO and/or Tg Abs positive, displayed subnormal (<10.3 pmol/l) FT₄ concentrations (Fig. 1, panels d and e).

Overall, 56/220 (25.4%) women exhibited IH over the course of gestation and anti-thyroid antibodies were detectable in only 4/56 (7.1%) of them.

Overall, 82/220 women (26/82 with OH/SCH and 56/82 with IH) were given substitutive L-T₄ (median T₄ dose 1.65 µg/kg per day). In all of them, serum TSH and/or FT₄ values returned to normal within 4 weeks and remained so during further follow up.

Obstetrical and neonatal outcome

Data relative to obstetrical and neonatal outcomes were obtained for 204/220 women and are shown in Table 2. No differences in either gestational or neonatal

![Figure 1](https://www.eje-online.org)

**Figure 1** Panels a–e show individual serum FT₄ and TSH values at first (week 5–12, panel a), second (week 13–19, panel b; week 20–26 panel c) and third (week 27–33, panel d; week 34-pregnancy term, panel e) trimester. The vertical dotted lines indicate the highest normal trimester-specific TSH value (2.3; 2.8 and 3.0 mIU/l at first, second and third trimester respectively). The horizontal dotted lines indicate the lowest normal trimester-specific FT₄ value (11.9; 10.4 and 10.3 pmol/l at first, second and third trimester respectively). Women found to be either hypothyroid or hypothyroxinemic throughout gestation were given substitutive L-T₄ and are indicated by white symbols (w). Untreated women are indicated by black symbols (v).
parameters were observed in the women who were found to be consistently euthyroid (129/204) throughout gestation or in those who received substitutive $\text{L-T}_4$ treatment for either OH/SCH (24/204) or IH (51/204).

**Risk of OH/SCH in antibody-positive pregnant women**

Of the 18/220 women who at presentation tested positive for TPO-Abs and/or Tg-Abs, 8/18 (44.4%) experienced OH/SCH, during either the first (5/8) or the second (3/8) trimester. Of the 202/220 antibody-negative women, 18/202 (8.9%) were diagnosed with OH/SCH. Therefore, the relative risk of OH/SCH in antibody-positive women was 5.0 ($\chi^2$ 20.02, $P!0.0005$).

Of the remaining 10/18 antibody-positive women, 4/18 (22.2%) exhibited IH, mostly throughout the second trimester, and 6/18 (33.3%) displayed no thyroid function abnormalities at any stage of gestation.

**Timing of OH/SCH occurrence and potential for misdiagnosing at early thyroid function testing**

The overall prevalence of OH/SCH over the course of gestation amounted to 11.8% (26/220). It is interesting to note that of those women experiencing hypothyroidism, just over half of them (15/26) were identified at the presentation. In further follow up, either OH or SCH could be detected in the residual 11/26 at both early (6/11, between weeks 13 and 19) and late (5/11, between weeks 20 and 26) phases of the second trimester. Consequently, 42.3% hypothyroid women would not have been diagnosed, if we had limited our observation to early thyroid function tests alone.

The frequency distribution of OH/SCH for each gestational period is shown in Fig. 2 (panel a).

As concerns IH, this mild condition of thyroid underfunction became progressively more common from the end of the first trimester onwards, peaking between weeks 20 and 26. Indeed, at presentation only seven women displayed FT$_4$ values below the 2.5 percentile for gestational age, the remaining 49/56 (87.5%) dropped to this limit later in gestation (Fig. 2, panel b).

**Discussion**

Our study evaluated the timing of maternal thyroid failure in a cohort of pregnant women from a mildly ID area who had never been tested for thyroid dysfunction prior to becoming pregnant. The main objective of the study was to assess the benefit of thyroid function
testing at early gestation only in identifying maternal thyroid dysfunction.

Very recently, an ad hoc Endocrine Society committee established consensus guidelines that strongly recommend maternal thyroid function screening in selected groups of women considered to be at high risk for thyroid dysfunction, mainly because of a personal or family history of autoimmune disease (13). However, the efficacy of this strategy has recently been called into question, by the results of a prospective study, which concludes that testing only high-risk pregnant women would cause nearly one third of cases of hypothyroidism during early gestation to escape detection (19, 20). The recommendations further state that screening should consist of TSH measurement 'performed before pregnancy when possible, or at the first prenatal visit' (13). This timing of intervention would certainly guarantee the prompt identification of women affected with thyroid insufficiency prior to becoming pregnant, but has the potential to overlook any women who might develop thyroid insufficiency in the subsequent stages of pregnancy. Indeed, pregnancy represents a challenge for the maternal thyroid, due to a progressive increase in hormone demand that can only be met by a very marked augmentation in hormone output. This endpoint is ensured by physiological adaptations of the thyroidal economy, provided that the thyroid gland is fully operative and iodine intake adequate (21).

The women included in this study were variously iodine-supplemented. In addition to the regular use of iodised salt, more than one half of them also received multivitamin compounds containing 100–150 µg of iodine. Median UIE at recruitment was consistent with mild iodine deficiency. About 8% of the women had detectable thyroid auto-antibodies. Overall, the prevalence of either overt or SCH was nearly 1.2% and almost 60% of the hypothyroid women were identified at recruitment. The remaining 40% became hypothyroid in the further follow up, namely over the course of the second trimester, and would not have been identified, if we had limited our observation to the first thyroid function test alone. Antithyroid autoantibodies were present in about one third of hypothyroid women (more or less equally distributed between the first and second trimesters), and in a small percentage of women who displayed only minor thyroid abnormalities (IH). Overall, thyroid autoimmunity was associated with a fivefold increased risk of hypothyroidism. Nonetheless, the vast majority of women experiencing either overt or SCH throughout gestation repeatedly tested negative for thyroid antibodies. This suggests that a feature other than thyroid autoimmunity, namely iodine deficiency, might play a major role in the occurrence of hypothyroidism in these women. It is reasonable to believe that the iodine needs of women experiencing thyroid underfunction throughout gestation were not fully met by their daily iodine intake and that the iodine stored in their thyroid gland was not sufficient to ensure adequate hormone synthesis and secretion for the whole gestational period. In other words, the occurrence of maternal thyroid insufficiency during the second trimester in women who proved euthyroid at very early testing might be explained by failure of the maternal thyroid to keep up with increased hormone demand due to an inadequate iodine supply. A similar mechanism might be involved in the occurrence of milder biochemical thyroid abnormalities, such as isolated hypothyroxinaemia, which in our series was observed in nearly one quarter of women, mainly from the end of first trimester onwards, although the cause of isolated hypothyroxinaemia is not fully understood.

Epidemiological data from either moderate or mild iodine deficient areas have shown that a critical reduction in maternal FT4, especially during early gestation, may not necessarily be matched by a proportional and simultaneous TSH increase. This is likely due to the fact that, over the first trimester, placental human chorionic gonadotropin stimulates the preferential ID-related thyroidal output of tri-iodothyronine (T3), which in turn, triggers negative feedback on pituitary TSH secretion. In these women, therefore, circulating T3 is normal or even slightly over the upper limit, TSH falls within the normal range, and the women are clinically euthyroid even when biochemically hypothyroxinemic (2). The causes of IH in women from iodine-sufficient areas (19, 22) are even less clear, though an iodine intake that does not meet the requirements of pregnancy cannot be categorically ruled out in these women either. It remains to be demonstrated whether or not the condition is in fact consistent with potential thyroid failure. It has recently been shown that mild IH does not affect pregnancy outcome (23). Conversely, present clinical and experimental evidence seems to suggest that early and prolonged (until week 24) maternal hypothyroxinemia is a risk factor for impaired foetal brain development (3, 22, 24–26). Moreover, other reports of poor developmental outcome in preterm babies indicate that a normal supply of maternal T3 continues to have an important protective role after midgestation (27, 28). Because of the potential irreversibility of foetal brain damage, we decided arbitrarily to give substitutive L-T4 treatment to women experiencing IH, in order to ensure FT4 levels similar to those observed in adequately iodine supplemented women at the same stage of pregnancy. We do not know whether or not this strategy of intervention improved obstetrical and neonatal outcomes, due to the lack of a control group of untreated hypothyroid/hypothyroxinemic women. Actually, no differences were observed in the pregnancy outcomes of either L-T4 treated or persistently euthyroid pregnant women or in their newborns. Nonetheless, this aspect was beyond the scope of our study, whose principal focus was on the timing of the occurrence of maternal thyroid underfunction. Accordingly, the main conclusion of our study is that in mildly ID areas thyroid
function testing early in gestation is only partly effective in identifying thyroid dysfunction in pregnant women, because maternal thyroid underfunction also occurs later in gestation in apparently healthy women and in the absence of thyroid autoimmunity. Of course, a strategy of systematic screening and monitoring of thyroid function in all pregnant women from mildly ID areas should first be justified by cost-benefit analyses specifically designed to clarify this issue. Nonetheless, since iodine deficiency is the main cause of maternal thyroid insufficiency all over the world (29, 30), basic prevention should consist of adequate and long-term iodine supplementation of women of child-bearing age prior to becoming pregnant, in order to permit the accumulation of sufficient iodine stores to meet the increased needs of both mother and foetus.

Declaration of interest
The authors have nothing to disclose.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References
10. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS & Weissman NJ. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. Journal of the American Medical Association 2004 291 228–238.

27 den Ouden AL, Kok JH, Verkerk PH, Brand R & Verloove-Vanhorick SP. The relation between neonatal thyroxine levels and neurodevelopmental outcome at 5 and 9 years in a national cohort of very preterm and/or very low birth weight infants. *Pediatric Research* 1996 **39** 143–145.


Received 15 January 2009
Accepted 26 January 2009